314 results about "Potentiator" patented technology

The invention provides a kit and a method for detecting common fusion genes of lymphoid leukemia based on a multiple digital PCR (Polymerase Chain Reaction) method. By constructing a synergistic effect mechanism of the primer and the fluorescent probe and optimizing matching of the primer, the probe and a fluorescent marker, non-specific binding among amplification products is effectively avoided. A composite reaction aid with a specific formula, namely a PCR enhancer, is innovatively introduced, so that the amplification efficiency and specificity of a multiple detection system are remarkably improved. According to the kit provided by the invention, the integrated detection capability on seven fluorescent channels, namely Atto 425, VIC, FAM, ROX, CY5, CY5.5 and CY7, is realized in a single-hole design. By innovatively constructing an ROX + CY5 and Atto425 + VIC dual-channel joint detection system, when the ROX and CY5 channels or Atto425 and VIC channels in the same detection hole simultaneously present positive signals, two additional detection targets can be specifically interpreted. The innovative detection strategy based on channel combination enables the kit to realize precise detection of 18 fusion genes only through two detection holes in a breakthrough manner.

The invention relates to the field of nano-drug delivery preparations, in particular to a traditional Chinese medicine transdermal drug delivery preparation based on a nano-coating technology and a preparation method thereof, the traditional Chinese medicine transdermal drug delivery preparation comprises a liposome-metal organic framework composite carrier, and the composite carrier comprises traditional Chinese medicine active ingredients; a meridian point targeted transdermal enhancer; an iontophoresis device for dynamically sensing skin impedance; the invention relates to an intelligent administration time sequence control system based on a traditional Chinese medicine midnight-noon ebb-flow theory. The liposome-metal organic framework composite carrier is adopted, the similar structure of liposome and skin and the high specific surface area of MOF are fully utilized, efficient encapsulation and transdermal absorption of active ingredients of traditional Chinese medicine are achieved, and compared with a traditional transdermal patch, the drug transdermal absorption rate is increased by 3-5 times.

The invention belongs to the technical field of biological medicines, and particularly relates to application of bleomycin or bleomycin analogues in preparation of an immunopotentiator. The invention also provides a pharmaceutical composition and application of the pharmaceutical composition in preparation of drugs for treating and / or preventing cancers. The pharmaceutical composition comprises bleomycin, bleomycin analogues or a combination thereof and an anti-tumor immunotherapeutic agent.

The invention discloses a dendrobium huoshanense polysaccharide nanoemulsion immunologic adjuvant and a preparation method thereof. The dendrobium huoshanense polysaccharide nanoemulsion immunologic adjuvant is prepared from the following raw materials in percentage by mass: 0.1%-2.0% of dendrobium huoshanense polysaccharide, 20%-30% of a surfactant, 5%-10% of a cosurfactant, 5%-10% of an oil phase and the balance of deionized water. The preparation method of the nano-emulsion is simple and easy to implement, equipment is easy to control, the cost is low, and the obtained nano-emulsion is small in droplet particle size, high in stability and capable of improving the spleen lymphocyte proliferation activity of immunocompromised mice. The nanoemulsion can significantly improve the immunomodulatory activity of dendrobium huoshanense polysaccharide, and has the potential of developing immunopotentiators, thereby promoting the development and utilization of traditional Chinese medicine resources and active components thereof.

The invention discloses an immunogenic composition containing an adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises self-assembled gE virus-like nanoparticles, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the self-assembled gE virus-like nanoparticles are formed by polymerizing and assembling monomers; the monomers include VZV gE, a linker peptide (SGS), and a VZV gI polypeptide containing a Th epitope. The immunogenic composition can be applied to varicella-zoster virus vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, and the use of an immunopotentiator in the vaccine can be reduced, so that the clinical side reaction of the vaccine is lower; in addition, the vaccine can induce a gI specific antibody and gI specific CMI reaction, and the effectiveness of the vaccine can be further improved. In short, the immunogenic composition has good clinical application potential.

The invention belongs to the technical field of vaccine adjuvants, and particularly relates to a water-in-oil-in-water adjuvant, a veterinary vaccine and a preparation method thereof.The water-in-oil-in-water adjuvant is prepared from, by weight, 0.5%-7.5% of a hydrophilic composite surfactant, 0.6%-9.8% of an oleophylic composite surfactant, 70%-85% of mineral oil and the balance water; and the mineral oil also comprises the following components in concentration: a reinforcing agent of 0.45-0.9 g / ml and a stabilizing agent of 2-6.9 g / L, wherein the water-in-oil-in-water adjuvant forms a gelatinous structure under the regulation of the stabilizer and is a non-Newtonian fluid of which the viscosity is not higher than 25cp; the adjuvant shows the non-flowing fluid characteristic through the stabilizer, the rheological property of the produced vaccine is enhanced, the stability of the vaccine is improved, on the premise that the hydrophilic surfactant and the oleophylic surfactant are balanced, the natural polymer enhancer is added, and on the premise that the adjuvant viscosity is reduced and granuloma side reaction is not prone to being generated, the stability of the vaccine is improved. Short-term immunity and long-term immunity can be induced at the same time, and the application of the water-in-oil-in-water adjuvant in the field of veterinary vaccines is expanded.

Systems and methods for infection prevention and treatment in biological conduits using electroporation or pulsed field ablation (PFA). The system includes an elongate member, such as a dialysis catheter, vascular access device, or peritoneal dialysis conduit, with at least one electrode positioned along, within, or around the member. A control unit applies pulsed electric fields to inhibit microbial colonization, disrupt bacterial biofilms, and alter permeability of bacterial or endothelial cells to enhance sterility or fluid exchange. The system may use real-time impedance monitoring, microbial detection, or fluid composition analysis to adjust electroporation parameters. Electroporation may synchronize with dialysis cycles or antimicrobial lock solutions. The method includes automated, clinician-controlled, or sensor-triggered treatments to reduce infections and improve device longevity. The system provides an alternative or augment to antibiotics, reducing the risk of drug-resistant infections while improving the longevity and safety of medical implants.

A system and method for providing an enhancing or contrast agent advisability indicator. Subject data for a subject is processed using an AI-based model to obtain an indication of whether a medical imaging procedure for the subject requires an enhancing or contrast agent. The enhancing or contrast agent advisability indicator is generated with respect to one or more target pathologies assessed in the medical imaging procedure.

The present invention relates to a product containing elderberry extract and a potentiator selected from pepper extract, ginger extract, curcuma extract and citrus plant extract.

The present disclosure provides compounds, compositions, and methods for treating or preventing neurological disorders in a patient. The disclosed methods include administration to a subject suffering from a neurological disorder of a compound disclosed herein.

The invention discloses an immunogenic composition containing a composite adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises a gE-gI fusion protein, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the gE-gI fusion protein comprises a VZV gE, a connecting peptide and a VZV gI. The immunogenic composition provided by the invention only contains one immunopotentiator, can be applied to VZV vaccines, and solves the problems of relatively weak gE immunogenicity and relatively large clinical side reaction of the vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, but the vaccine contains fewer immunopotentiators and has lower clinical side effects; in addition, the vaccine can also induce a gI specific antibody and gI specific CMI reaction, which is beneficial to further improvement of the effectiveness of the vaccine. In short, the immunogenic composition has good clinical application potential.

Provided herein are compounds, including compounds of any of the formulae described herein (e.g., Formula (I), e.g., Formula (I")), and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, hydrates, isotopically labeled derivatives, and prodrugs thereof. Compounds provided herein can act as potentiators of voltage-gates potassium channels (e.g., Kv7 potassium channels such as Kv7.2 / Kv7.3) and are therefore useful in the treatment and / or prevention of diseases, disorders, and conditions (e.g., diseases, disorders, and conditions associated with Kv7 potassium channel dysfunction).

The invention belongs to the technical field of biological medicine, and particularly relates to application of actinomycin D in preparation of a ctDNA detection sensitizer. The invention provides a ctDNA release method based on actinomycin D as an enhancer, which can significantly improve the release level of ctDNA in early small-volume tumors and tiny residual lesions, thereby improving the sensitivity and positive detection rate of liquid biopsy in MRD detection. Under an extremely low dosage, the ActD can generally promote a plurality of human tumor cells to release ctDNA under the condition of not causing obvious cell death, and has good biological safety and adaptability. The method is especially suitable for tiny, biological inert or anatomical position hidden focuses which are difficult to identify by iconography, namely blind area patient groups in disease monitoring, and has a wide clinical application prospect.

The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations.

To provide the use of a CBR1 agonist as an adjuvant and an adjuvant composition.SOLUTION: A compound represented by formula (1): Wherein R represents a cyclopropyl group or a 2-chloroethyl group. The antibody induction-promoting agent contains a compound represented by general formula (I) as an active ingredient.SELECTED DRAWING: None

The application discloses a kind of composition with immunoregulation and anti-aging function and preparation method thereof, and core component is marine collagen peptide, fusion polypeptide CPF-1, targeting senescent cell monoclonal antibody mAb Senolix, five gallate acyl glucose (PGG) and Hericium erinaceus polysaccharide.Fusion polypeptide CPF-1 is designed by domain fusion strategy, with collagen binding, immune activation and antibacterial function;Monoclonal antibody mAb Senolix targets the surface antigen p16^(INK4a) of senescent cell, and removes senescent cell by ADCC effect.The composition significantly improves immune cell activity, promotes collagen synthesis and reduces chronic inflammation through the synergistic effect of multiple components, and shows excellent immunoregulation and anti-aging effect in in vitro cell model and immunosuppressed mouse model, and can be used for developing immune enhancer, anti-aging drug or functional food.

The present application relates to an atomization device, comprising a first atomization source for atomizing a non-water-absorbing target substrate, a second atomization source for atomizing a reinforcing agent containing a water-absorbing agent, an air outlet for outputting a mixed aerosol, a first air outlet channel communicating the first atomization source and the air outlet, and a second air outlet channel communicating the second atomization source and the air outlet. The first air outlet channel and the second air outlet channel have a junction. Since the reinforcing agent contains a water-absorbing agent, the generated mixed aerosol has water-absorbing property. Since the mixed aerosol has water-absorbing property, it has water-absorbing growth performance and water-absorbing deposition effect, thereby significantly improving the overall deposition and absorption efficiency of the non-water-absorbing target substrate in the human respiratory tract.

The invention belongs to the technical field of natural pharmaceutical chemistry and medical application, and discloses a quinolone antibiotic synergist and application thereof in preparation of a medicine for treating bacterial infection. The structural formula of the quinolone antibiotic synergist is shown in the specification. The quinolone antibiotic synergist can effectively inhibit the activity of a staphylococcus aureus efflux pump, and the survival rate of mice infected with staphylococcus aureus can be remarkably increased when the quinolone antibiotic synergist is combined with quinolone antibiotics for use.

The invention belongs to the technical field of chemiluminescence immunoassay, and particularly relates to application of a luminescence retarder in improving development quality of solid-phase membrane immunodetection. According to the invention, when the concentration of the delay agent is fixed, the time of luminescence starting delay and the concentration of the enzyme catalyst are in nonlinear negative correlation, that is, the delay time is obviously increased along with the reduction of the enzyme concentration. The nonlinear negative correlation is suitable for luminescent systems of different reinforcing agents. Benefited from the enzyme concentration dependent luminescence delay effect, the chemiluminescence liquid with the delay effect is used for improving the development quality of solid-phase membrane immunodetection for the first time, noise and background signals are suppressed, and the chemiluminescence liquid has wide application value in the aspect of solid-phase membrane immunodetection.

GD2 specific chimeric antigen receptor effector cells for the treatment of solid tumors, possibly in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor. The invention relates to a GD2-specific chimeric antigen receptor (GD2. CAR) effector cell for use in the treatment of solid tumors, in particular in the treatment of extracranial GD2 + tumors, such as soft tissue sarcoma and osteosarcoma, neuroblastoma, melanoma, lung cancer, bladder cancer and retinoblastoma, and brain tumors. In addition, the present invention also relates to the use of the GD2. CAR genetically modified effector cell in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor for the treatment of solid tumors.

The present invention describes the synthesis and biological evaluation of new substituted pyridine derivatives as foxj1 activity enhancers. In embodiments, novel pyridine derivatives were synthesized and the ability thereof to enhance foxj1 activity was evaluated. The novel pyridine derivatives synthesized in the present invention not only exhibited excellent activity but also exhibited excellent metabolic safety and pharmacokinetic profile in a Tg (foxj1: egfp) transgenic zebrafish animal model. In addition, the novel pyridine derivatives synthesized in the present invention enhanced cilia-promoting capability in a motile ciliated cell differentiation experiment in which mouse tracheal epithelial cells (mTECs) were isolated from the airways of mice and cultured by ALI. As a result, a series of foxj1 activity enhancers with substituted pyridine skeleton has the potential to be developed as preventive and therapeutic agents for respiratory diseases.

Disclosed herein, in some aspects, are methods of treating autoimmune diseases or conditions using TCR targeting molecules or cells expressing TCR targeting molecules. TCR targeting molecules can comprise a moiety that binds to a TCR variable beta chain (TCRBV) or a TCR variable alpha chain (TCRAV). TCR targeting molecules can further comprise one, two or all of: (ii) an immune cell engager; (iii) a cytokine inhibitor molecule; (iv) a cytotoxic agent; and / or (v) a death receptor signal enhancer. Additionally, disclosed herein, in some aspects, are nucleic acids encoding the same, and methods of producing the aforesaid molecules.

The invention belongs to the technical field of biomedical detection, and discloses a TAR DNA binding protein 43 detection method based on LC-MS / MS and application. The detection method comprises the following steps: taking a biological matrix to be detected, and filtering to obtain filtrate; adding an ion enhancer into the obtained filtrate, oscillating and incubating, adding a protein precipitant, and separating precipitated protein; adding trypsin into the precipitated protein, and incubating to obtain a sample containing a characteristic peptide fragment; and detecting the TAR DNA binding protein 43 in the sample by adopting liquid chromatography-triple quadrupole mass spectrometry. According to the method, the TDP-43 is specifically detected and quantified by adopting a liquid chromatography-tandem mass spectrometry technology, so that the excellent effects of efficiently detecting and accurately quantifying the TDP-43 and improving the detection sensitivity and stability are achieved. The method can be applied to the fields of in-vitro diagnosis of neurodegenerative diseases, pathological mechanism research and therapeutic drug development.

The invention relates to the technical field of biological medicine, in particular to application of flufenamic acid in preparation of a polymyxin E antibacterial synergist. The invention discloses an application of flufenamic acid in preparation of a polymyxin E antibacterial synergist, the flufenamic acid has no obvious antibacterial effect on salmonella when being independently used, but the flufenamic acid and polymyxin E can enhance the antibacterial activity of the polymyxin E on the salmonella and reduce the use dosage of the polymyxin E when being jointly used in and out of an animal body, so that the antibacterial effect of the polymyxin E on the salmonella can be enhanced. The antibacterial activity of the polymyxin E on salmonella is enhanced, and the drug resistance of the polymyxin E is inhibited. Flurfenamic acid is approved to be used for other purposes as FDA, and when the flurfenamic acid is combined with polymyxin E, the flurfenamic acid has the characteristic of high safety, and meanwhile, the generation of the drug resistance of the polymyxin E drugs can be effectively avoided. The invention provides a basis for mining a new antibacterial prevention and control strategy for the polymyxin E drug-resistant bacteria.

The present invention relates to fusion proteins for use in the induction of immune responses and in the treatment of cancer, and in particular as immunopotentiators and for use in the induction of humoral immune responses and cell-mediated immune responses.

The application belongs to the technical field of medicine, and relates to a use of minocycline in preparation of an antitumor synergist. The minocycline, as the antitumor synergist, has a synergistic effect with 5-fluorouracil and gemcitabine, significantly enhances the curative effect of an antitumor drug, reduces the dosage of the antitumor drug, and reduces side effects of the antitumor drug on the body or damage of the antitumor drug to normal tissue cells.

A noninvasive ophthalmic formulation, comprising a chelator (such as EDTA and its salts), a transport enhancer (such as Methyl Sulfonyl Methane; MSM), a second polyoxyalkylene permeation enhancer such as propylene glycol capable of enhancing permeation through lipid-thickened ocular membranes, a thickening agent such as hydroxyethyl cellulose (HEC) and a surfactant such as polysorbate 80, is provided. The novel combination of the ingredients unexpectedly and beneficially reduces symptoms associated with early-stage, age-related cataracts. Methods for treating cataracts with compositions of the invention and measurement of improved visual function by measuring contrast sensitivity (CS) are provided.

The invention belongs to the technical field of medical dressings, and particularly relates to a gel dressing for relieving postoperative lymphedema of breast cancer and a preparation method thereof.The gel dressing is prepared from, by weight, 0.1-0.5 part of active medicine, 8-12 parts of modified matrix, 0.2-0.8 part of dopamine hydrochloride, 2 parts of dispersing agent and 0.5-1.5 parts of enhancer, menthol with functions of promoting infiltration and inducing diuresis to alleviate edema is used for modifying mussel mucoprotein with good biocompatibility, the crosslinking gelling property of the mussel mucoprotein is improved, meanwhile, along with hydrolysis breakage of covalent bonds, gel slowly collapses to release active drugs, and the active drugs and the menthol cooperate with each other, and the postoperative lymphedema of breast cancer is treated from various mechanism ways.

The invention relates to the technical field of precipitation separation equipment, and discloses an immunopotentiator crude product precipitation separation device which comprises a precipitation tank used for precipitation separation of an immunopotentiator; the sealed tank body is used for being in sealed butt joint with the top of the precipitation tank body, and a feeding opening is formed in the top of the sealed tank body; the cleaning mechanism is used for covering the top of the precipitation tank body and cleaning the interior of the precipitation tank body; the lifting and rotating mechanism is used for switching butt joint of the sealing tank body or the cleaning mechanism and the settling tank body, the lifting and rotating mechanism is arranged between the sealing tank body and the cleaning mechanism, and the lifting and rotating mechanism is connected with the sealing tank body and the cleaning mechanism in a one-to-one mode through connecting rods. Maintenance and inspection are convenient, the daily maintenance process is greatly simplified, the working efficiency is improved, meanwhile, the mechanical damage risk possibly caused by frequent disassembly and assembly is reduced, and the service life of equipment is prolonged.

The invention belongs to the technical field of antibacterial synergists, and discloses application of ramoplanin as a colistin antibacterial synergist. The invention provides a treatment strategy for combined use of ramoplanin as a polymyxin drug sensitizer in treatment of gram-negative bacterial infection, and in a test of combined use of ramoplanin and colistin for detection of a bacterial sterilization curve and the integrity of a bacterial outer membrane, the concentration of the ramoplanin is low and is only 16 [mu] g / mL; in the aspect of the antibacterial effect, the FICI index is relatively low, and after the ramoplanin and the colistin are jointly used, the MIC (Minimum Inhibitory Concentration) of the colistin can be reduced by 16 times at most. The research shows that ramoplanin is a promising antibiotic sensitizer, and can be used in combination with the polymyxin drug colistin to resist the colistin drug resistance problem of escherichia coli, salmonella and klebsiella pneumoniae.